CSIMarket
 


Sutro Biopharma Inc   (STRO)
Other Ticker:  
 

Sutro Biopharma Inc 's Leverage Ratio

STRO's quarterly Leverage Ratio and Total Liabilities, Equity growth


Due to net new borrowings of 2.97%, Leverage Ratio fell to 2.84, a new company high.

Within Biotechnology & Pharmaceuticals industry in the third quarter 2023, 125 other companies have achieved lower Leverage Ratio than Sutro Biopharma Inc in the III Quarter 2023. While Leverage Ratio total ranking has deteriorated compared to the second quarter 2023 from 2663 to 2924 .

Explain Leverage Ratio?
Who are STRO Customers?
What are STRO´s Total Liabilities?


STRO Leverage Ratio (Sep 30 2023)
III. Quarter
(Jun 30 2023)
II. Quarter
(Mar 31 2023)
I. Quarter
(Dec 31 2022)
IV. Quarter
(Sep 30 2022)
III. Quarter
Y / Y Equity Change -51.1 % -25.99 % -15.86 % -14.06 % -18.99 %
Y / Y Total Liabilities Change 86.8 % 75.68 % 107.2 % 113.74 % 94.53 %
Leverage Ratio MRQ 2.84 2 0.93 0.87 0.74
STRO's Total Ranking # 2924 # 2663 # 1439 # 1704 # 1516
Seq. Equity Change -27.38 % -16.56 % -14.58 % -5.52 % 9.89 %
Seq. Total Liabilities Change 2.97 % 79.71 % -9.11 % 11.07 % -3.16 %



Leverage Ratio third quarter 2023 Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry # 126
Healthcare Sector # 769
Overall Market # 2924


Leverage Ratio Statistics
High Average Low
2.84 0.71 0.17
(Sep 30 2023)   (Mar 31 2021)




Financial Statements
Sutro Biopharma Inc 's Equity $ 112 Millions Visit STRO's Balance sheet
Sutro Biopharma Inc 's Total Liabilities $ 319 Millions Visit STRO's Balance sheet
Source of STRO's Sales Visit STRO's Sales by Geography


Cumulative Sutro Biopharma Inc 's Leverage Ratio

STRO's Leverage Ratio for the trailling 12 Months

STRO Leverage Ratio

(Sep 30 2023)
III. Quarter
(Jun 30 2023)
II. Quarter
(Mar 31 2023)
I. Quarter
(Dec 31 2022)
IV. Quarter
(Sep 30 2022)
III. Quarter
Y / Y Equity TTM Growth -51.1 % -25.99 % -15.86 % -14.06 % -18.99 %
Y / Y Total Liabilities TTM Growth 86.8 % 75.68 % 107.2 % 113.74 % 94.53 %
Leverage Ratio TTM 1.48 1.07 0.84 0.71 0.57
Total Ranking TTM # 11 # 8 # 1582 # 4 # 6
Seq. Equity TTM Growth -27.38 % -16.56 % -14.58 % -5.52 % 9.89 %
Seq. Total Liabilities TTM Growth 2.97 % 79.71 % -9.11 % 11.07 % -3.16 %


On the trailing twelve months basis Due to the net new borrowings of 2.97% during the trailing twelve months finishing in the III Quarter 2023, cumulativeLeverage Ratio improved to 1.48, above the Sutro Biopharma Inc 's average Leverage Ratio.
Leverage Ratio is the average cumulative value over the last four quarters.

Among companies in the Biotechnology & Pharmaceuticals industry STRO recorded the lowest Leverage Ratio. While Leverage Ratio total ranking has deteriorated during the twelve months ending in the III Quarter 2023, compared to the prior period, from 8 to 11.

Explain Leverage Ratio?
Who are STRO Customers?
What are STRO´s Total Liabilities?

TTM Leverage Ratio Company Ranking
Within: No.
Within the Biotechnology & Pharmaceuticals Industry # 0
Healthcare Sector # 1
Within the Market # 11


trailing twelve months Leverage Ratio Statistics
High Average Low
2.16 0.71 0.19
(Jun 30 2019)   (Jun 30 2021)




Companies with similar Leverage Ratio in the quarter ending Sep 30 2023, within Biotechnology & Pharmaceuticals Industry Leverage RatioSep 30 2023 MRQ Total LiabilitiesSep 30 2023 MRQ Equity
Cidara Therapeutics Inc   6.90 $ 55.430  Millions$ 8.038  Millions
Halozyme Therapeutics Inc   6.60 $ 1,643.481  Millions$ 249.181  Millions
Precision Biosciences Inc  4.65 $ 135.281  Millions$ 29.063  Millions
Acorda Therapeutics Inc   3.83 $ 225.759  Millions$ 58.957  Millions
Windtree Therapeutics Inc  3.76 $ 28.134  Millions$ 7.484  Millions
Alector Inc   3.14 $ 509.840  Millions$ 162.555  Millions
Biomx Inc   3.09 $ 25.181  Millions$ 8.154  Millions
Humacyte Inc   3.04 $ 112.392  Millions$ 36.993  Millions
Sutro Biopharma Inc   2.84 $ 319.387  Millions$ 112.347  Millions
Pluri Inc   2.74 $ 30.211  Millions$ 11.038  Millions
Valneva Se  2.59 $ 371.633  Millions$ 143.637  Millions
Adaptimmune Therapeutics Plc  2.37 $ 208.509  Millions$ 88.129  Millions
Ladrx Corporation  2.18 $ 2.100  Millions$ 0.965  Millions
Curis Inc   2.00 $ 59.122  Millions$ 29.591  Millions
Meiragtx Holdings Plc  1.91 $ 175.308  Millions$ 91.886  Millions
Omega Therapeutics Inc   1.86 $ 141.765  Millions$ 76.043  Millions
Inhibrx Inc   1.85 $ 239.481  Millions$ 129.595  Millions
Estrella Immunopharma Inc   1.72 $ 17.281  Millions$ 10.069  Millions
Aptose Biosciences Inc   1.68 $ 13.100  Millions$ 7.776  Millions
X4 Pharmaceuticals Inc  1.55 $ 104.583  Millions$ 67.594  Millions
Orchard Therapeutics Plc  1.52 $ 122.008  Millions$ 80.258  Millions
Gilead Sciences Inc   1.50 $ 33,436.000  Millions$ 22,242.000  Millions
Cel sci Corporation  1.31 $ 17.313  Millions$ 13.215  Millions
Arcellx Inc   1.31 $ 348.090  Millions$ 266.128  Millions
Poseida Therapeutics Inc   1.27 $ 156.729  Millions$ 123.660  Millions
Adma Biologics Inc   1.22 $ 184.901  Millions$ 151.437  Millions
Autolus Therapeutics Plc  1.22 $ 220.089  Millions$ 180.518  Millions
Protalix Biotherapeutics inc   1.17 $ 44.820  Millions$ 38.247  Millions
Candel Therapeutics Inc   1.15 $ 26.539  Millions$ 23.022  Millions
Pharmacyte Biotech Inc   1.15 $ 42.110  Millions$ 36.768  Millions

Date modified: 2023-11-14T21:39:10+00:00



Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com